Диссертация (1140465), страница 24
Текст из файла (страница 24)
Barett, J.O. Draguesku et al. // Hepatology. – 1991. – Vol. 14. – 96A.164. Sidhu, S. Pentoxifylline reduces disease severity and prevents renal impairment in severe acute acloholic hepatitis: a double-blind placebo-controleld trial[Text] / S. Sidhu, K. Bhatia // Hepatology.– 2006. – Vol. 44. – 373A.165. Pentoxifylline for treatment of patients with advanced cirrhosis. A randomzied placebo controlled double blind trial [Text] / D.
Leebrec, D.Fabut, F.Oberti et al. // Hepatology. – 2007. – Vol. 46. – A249-A250.166. Pentoxifylline for alcoholic hepatitis [Text] / K. Whitfield, A. Rambaldi, J. Wetterslev et al. // Cochrane Database Syst. Rev.– 2009. – CD007339.167. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial [Text] / B.K. De, S. Gangopadhyay, D.
Dutta et al.//World. J. Gastroenterol.– 2009. – Vol. 15. – P. 1613-1619.168. Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: arandomised, non-inferiority, open trial [Text] / S.H. Park, D.J. Kim, Y.S. Kim et al.// J. Hepatol.– 2014.
– Vol. 61. – P. 792-798. 169. Early switch to pentoxifylline in patients with severe alcoholic hepatitisis inefficient in non-responders to corticosteroids [Text] / A. Louvet, E. Diaz, S.Dharancy et al. // J. Hepatol.– 2008. – Vol. 48. – P. 465-470. 142170. Corticosteroid plus pentoxifylline is not better than corticosteroid alonefor improving survival in severe alcoholic hepatitis (COPE trial) [Text] / S.S.Sidhu, O. Goyal, P. Singla et al. // Dig. Dis. Sci.– 2012. – Vol. 57.
– P. 1664-1671.171. Prednisolone with vs without pentoxifylline and survival of patientswith severe alcoholic hepatitis: a randomized clinical trial [Text] / P. Mathurin, A.Louvet, A. Duhamel et al. // JAMA.– 2013. – Vol. 310. – P. 1033-1041. 172. Systematic review: pentoxifylline for the treatment of severe alcoholichepatitis [Text] / R. Parker, M.J. Armstrong, C. Corbett et al.
// Aliment.Pharmacol.– 2013. – Vol. 37. – P. 845-854. 173. Comparative effectiveness of pharmacological interventions for severealcoholic hepatitis: a systematic review and network meta-analysis [Text] / S.Singh, M.H. Murad, A.K. Chandar et al. // Gastroenterology.– 2015. – Vol. 149. –P. 958-970 e12. 174. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis andinflammation caused by chronic exposure to ethanol in the rat [Text] / Y. Iimuro,R.M. Gallucci, M.I. Luster et al. // Hepatology.– 1997.
– Vol. 26. – P. 1530-1537.175. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severealcoholic hepatitis [Text] / H. Tilg, R. Jalan, A. Kaser et al. // J. Hepatol.– 2003. –Vol. 38. – P. 419-425. 176. Infliximab monotherapy for severe alcoholic hepatitis and predictors ofsurvival: an open label trial [Text] / P. Sharma, A. Kumar, B.C. Sharma et al. // J.Hepatol.– 2009. – Vol.
50. – P. 584-591. 177. A pilot study of the safety and tolerability of etanercept in patients withalcoholic hepatitis [Text] / K.V. Menon, L. Stadheim, P.S. Kamath et al. // Am. J.Gastro- enteral.– 2004. – Vol. 99. – P. 255-260. 178. A double-blind randomized controlled trial of infliximab associatedwith prednisolone in acute alcoholic hepatitis [Text] / S. Naveau, S. CholletMartin, S. Dharancy et al. // Hepatology.– 2004. – Vol. 39. – P. 1390-1397.
143179. A randomized, double-blinded, placebo-controlled multicenter trial ofetanercept in the treatment of alcoholic hepatitis [Text] / N.C. Boetticher, C.J.Peine, P. Kwo et al. // Gastroenterology.– 2008. – Vol. 135. – P. 1953-1960. 180. Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy [Text] / P.
Akerman, P. Cote, S.Q. Yang et al. // Am. J.Physiol.– 1992. – Vol. 263. – G579–G585. 181. Loguercio, C. Oxidative stress in viral and alcoholic hepatitis [Text] /C. Loguercio, A. Federico // Free Radic. Biol. Med.– 2003. – Vol. 34. – P. 1-10. 182. A randomized trial of antioxidant therapy alone or with corticosteroidsin acute alcoholic hepatitis [Text] / S. Stewart, M. Prince, M.
Bassendine et al. // J.Hepatol.– 2007. – Vol. 47. – P. 277-283. 183. A randomized placebo-controlled trial of vitamin E for alcoholic hepatitis [Text] / E. Mezey, J.J. Potter, L. Rennie-Tankersley et al. // J. Hepatol.– 2004. –Vol. 40. – P. 40-46. 184. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis[Text] / E. Nguyen-Khac, T. Fevenot, M.A. Piquet et al. // N.
Engl. J. Med.– 2011.– Vol. 365. – P. 1781-1789. 185. Shah, V.H. Managing alcoholic liver disease [Text] / V.H. Shah // Clin.Mol. Hepatol. – 2015. – Vol. 21. – P. 212-219.186. S-Adenosylmethionine, cytokines, and alcoholic liver disease[Text] /C.J. McClain, D.B. Hill, Z. Song, et al. // Alcohol.– 2002. – Vol. 27, No. 3. – P.185-192. 187. Song, Z. S-Adenosylmethionine protects against acetaminopheninduced hepatotoxicity in mice[Text] / Z. Song, C.J. McClain, T. Chen // Pharmacology. – 2004.
– Vol. 71, No. 4. – P. 199-208. 188. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial[Text] / J.M. Mato, J. Camara,D.P. Fernandez, et al. //J. Hepatol.– 1999. – Vol. 30, No. 6. – P.
1081-1089. 144189. Craig, S.A. Betaine in human nutrition[Text] / S.A. Craig // Am. J.Clin.Nutr.– 2004. – Vol. 80. – P. 539-549. 190. Hepatocyte proliferation as an indicator of outcome in acute alcoholichepatitis [Text] / J.W. Fang, G.L. Bird, T. Nakamura et al. // Lancet.– 1994. – Vol.343. – P. 820-823. 191. Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis [Text] / L. Dubuquoy, A. Louvet, G. Lassailly et al. // Gut.
– 2015. – Vol. 64. – P. 1949-1960. 192. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial [Text] / J.C. Trinchet, B. Balkau, R.E. Pouponet al. // Hepatology. – 1992. – Vol. 15. – P. 76-81. 193. Insulin and glucagon infusion in acute alcoholic hepatitis: a prospectiverandomized controlled trial [Text] / G. Bird, J.Y. Lau, J. Koskinas et al.
// Hepatology.– 1991. – Vol. 14. – P. 1097-1101. 194. Rambaldi, A. Anabolic-androgenic steroids for alcoholic liver disease:a Cochrane review [Text] / A. Rambaldi, G. Iaquinto, C. Gluud // Am. J. Gastroenterol.– 2002. – Vol. 97. – P. 1674-1681.195. Orrego, H. Propylthiouracil treatment for alcoholic hepatitis: the case ofthe missing thirty [Text] / H.
Orrego, Y. Israel // Gastroenterology. – 1982. – Vol.83. – P. 945-956. 196. Double-blind, controlled trial of propylthiouracil in patients with severeacute alcoholic hepatitis [Text] / P. Halle, P. Pare, E. Kaptein et al. // Gastroenterology.– 1982.
– Vol. 82. – P. 925-931. 197. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: arandomized pilot study [Text] / V. Singh, A.K. Sharma, R.L. Narasimhan et al. //Am. J. Gastroenterol.– 2014. – Vol. 109. – P. 1417-1423. 198. Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis [Text] / C.K.145Kedarisetty, L. Anand, A.
Bhardwaj et al. //Gastroenterology.– 2015. – Vol. 148. –P. 1362-1370 e7.199.Cederbaum,A.I.HepatoprotectiveeffectsofS-adenosyl-L-methionineagainstalcohol- andcytochromeP450 2E1-inducedliverinjury[Text] /A.I. Cederbaum // WorldJ. Gastroenterol. – 2010. – Vol. 16 (11). – P. 1366–1376.200. Lieber,C.S. S-adenosyl-L-methionine: itsroleinthetreatmentofliverdisorders[Text] / C.S. Lieber// Am. J.
Clin. Nutr. – 2002. – Vol. 76 (5). – P. 1183S–1187S.201. Drug-induced liver injury in hospitalized patients with notably elevatedalanine aminotransferase [Text] / N.-M.Xu, Y.Chen, J.Xu, Q.Zhuu // World J. Gastroenterol. – 2012. – Vol. 18 (41). – P. 5972–5978.202. Иванян, А.Н. Беременность и заболевания печени [Текст] / А.Н.Иванян, Р.Р. Абузяров, Е.Н. Абузяров. – Смоленск, 2003.203. Кузьмин, В.Н.
Варианты клинического течения, диагностика и лечебная тактика острого жирового гепатоза беременных [Текст] / В.Н. Кузьмин, Л.В. Адамян // Акушерство и гинекология. – 2009. – № 1. – С. 25-29.204. Гуськова, Т.А. Токсикология лекарственных средств [Текст] / Т.А.Гуськова. – Москва, 2008. – 196 с.205. Методические рекомендации по изучению общетоксического действия лекарственных средств [Текст] / Е.В. Арзамасцев, И.В. Березовская,О.Л. Верстакова и др. / Руководство по доклиническому изучению лекарственых средств. Под ред. А.Н.
Миронова. – М.: Гриф и Ко, 2012. – С. 13-51.206. Лабораторные животные. Разведение, содержание и использование[Текст] / И.П. Западнюк, В.И. Западнюк, Е.А. Захария, Б.В. Западнюк. Изд. 3,перераб. и доп. – Киев: «Вища школа», 1983. – 383 с.207. Staples, R.E. Detection of visceral alterations in mammalian fetuses[Text] / R.E. Staples // Teratology. – 1974. – Vol. 9. – P.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
